Palvella Therapeutics (PVLA) Payables (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Payables of $5.4 million for Q1 2026, down 15.2% year-over-year from $6.4 million in Q1 2025, and down 19.85% quarter-over-quarter from $6.8 million in Q4 2025.
Palvella Therapeutics (PVLA) Payables (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Payables for 14 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 15.2% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (down 15.2% YoY), while the FY2025 annual figure was $6.8 million, up 3.46% from the prior year.
- Payables retreated to $5.4 million in Q1 2026 per PVLA's latest filing, from $6.8 million in the prior quarter.
- Across five years, Payables topped out at $7.6 million in Q2 2023 and bottomed at $801000.0 in Q3 2024.
- Historically, Payables has averaged $4.2 million across 5 years, with a median of $4.5 million in 2022.
- Annual changes were most pronounced in 2024 — Payables slumped 87.26% — and 2025, when it surged 611.24%.
- Palvella Therapeutics' Payables stood at $4.2 million in 2022, then plunged by 77.47% to $936000.0 in 2023, then surged by 601.28% to $6.6 million in 2024, then climbed by 3.46% to $6.8 million in 2025, then decreased by 19.85% to $5.4 million in 2026.
- Business Quant data shows PVLA's Payables at $5.4 million in Q1 2026, $6.8 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 6.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.79 Mn |
| Mar 31, 2026 | 5.44 Mn |
| Dec 31, 2025 | 6.79 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 6.54 Mn |
| Mar 31, 2025 | 6.42 Mn |
| Dec 31, 2024 | 6.56 Mn |
| Sep 30, 2024 | 801,000.00 |
| Jun 30, 2024 | 969,000.00 |
| Mar 31, 2024 | 1.52 Mn |
| Dec 31, 2023 | 936,000.00 |
| Sep 30, 2023 | 2.82 Mn |
| Jun 30, 2023 | 7.60 Mn |
| Mar 31, 2023 | 5.83 Mn |
| Dec 31, 2022 | 4.15 Mn |
| Sep 30, 2022 | 3.64 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | 4.50 Mn |
| Dec 31, 2021 | 8.61 Mn |
| Sep 30, 2021 | 3.56 Mn |